Xuanzhu Pharma Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Unnatural Products Inc. has synthesized cell-permeable cyclic peptides acting as E3 ubiquitin-protein ligase Mdm2 (Hdm2) and/or Mdm4 (Mdmx) inhibitors reported to be useful for the treatment of cancer.
Biocryst Pharmaceuticals Inc. has disclosed imidazole derivatives acting as activin receptor-like kinase 2 (ALK-2; ActR-IA) inhibitors reported to be useful for the treatment of diffuse intrinsic pontine glioma, spondyloarthritis and fibrodysplasia ossificans progressiva.
Researchers from Hangzhou Healzen Therapeutics Co. Ltd. and Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. presented the discovery and preclinical characterization of a next-generation Bcl-2 inhibitor, HZ-L105, being developed for the treatment of hematological cancers.
Trastuzumab-based chemotherapy has demonstrated clinical benefits in the treatment of HER2+ breast cancer. There is a percentage of patients who do not respond to therapy and have a poorer prognosis than those who respond. To better understand the mechanisms behind trastuzumab resistance, researchers in China studied the role of transcription elongation factor A protein-like 9 (TCEAL9) in resistance to trastuzumab-based chemotherapy in HER+ breast cancer.
Tumors have a lower interstitial pH compared to healthy tissues, with tumor acidity having emerged as a driver of tumor progression as it can lead to tumor immune evasion. Solute carrier family 4 member 4 (SLC4A4), which encodes a sodium bicarbonate cotransporter involved in pH regulation and homeostasis in normal tissue, was the focus of studies in pancreatic cancer resistance in in vivo preclinical models. Researchers tested the impact of Slc4a4 deletion in cancer cells on tumor growth, anticancer immunity and response to immunotherapy in murine models of pancreatic ductal adenocarcinoma (PDAC).
Orgenesis Inc. and Kurve Therapeutics Inc. have announced promising preclinical study results for intranasal administration of a cell-based oncolytic virus-bearing product.
Inhibitors of cyclin-dependent kinase 4 (CDK4) and CDK6, such as palbociclib, have significantly improved progression-free survival of several breast cancer types, such as hormone receptor-positive, HER2-negative luminal breast cancers, with about 40% being unresponsive or refractory to therapy; the main cause of resistance is the selection of mutant clones in the target oncoprotein.
3D Medicines Inc. has raised HK$408 million (US$52.5 million) in a listing on the Hong Kong Stock Exchange. Its shares opened at HK$29 apiece, jumped by more than 20% by the middle of the day, and closed at HK$31.45 on the first trading day of Dec. 15.
RSS
